Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTPSTTempest Therapeutics$0.77-8.1%$0.87$0.70▼$6.00$36.66M-1.832.10 million shs521,142 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTPSTTempest Therapeutics0.00%-6.05%-2.36%-8.19%-79.19%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTPSTTempest Therapeutics2.7347 of 5 stars3.55.00.00.01.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTPSTTempest Therapeutics 3.00Buy$9.331,108.82% UpsideCurrent Analyst Ratings BreakdownLatest TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$13.00 ➝ $7.003/28/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $16.00(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTPSTTempest Therapeutics-$29.49M-$1.50N/AN/AN/AN/A-187.44%-82.61%4/1/2025 (Estimated)Latest TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024TPSTTempest Therapeutics-$0.24-$0.31-$0.07-$0.31N/A$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTPSTTempest TherapeuticsN/A1.691.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipTPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTPSTTempest Therapeutics2043.64 million41.59 millionOptionableTPST HeadlinesRecent News About These CompaniesHC Wainwright Issues Pessimistic Forecast for Tempest Therapeutics (NASDAQ:TPST) Stock PriceMarch 30 at 1:47 AM | americanbankingnews.comTempest Therapeutics (NASDAQ:TPST) Given New $7.00 Price Target at ScotiabankMarch 29 at 4:21 AM | americanbankingnews.comTempest Therapeutics price target lowered to $7 from $13 at ScotiabankMarch 28 at 10:59 PM | markets.businessinsider.comTempest Therapeutics price target lowered to $16 from $47 at H.C. WainwrightMarch 28 at 5:58 PM | markets.businessinsider.comTempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 28 at 5:36 AM | finanznachrichten.deWilliam Blair Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)March 28 at 5:36 AM | markets.businessinsider.comTempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 27 at 4:10 PM | globenewswire.comTempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comTempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495March 13, 2025 | markets.businessinsider.comFDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)March 13, 2025 | globenewswire.comFDA Fast Tracks Amezalpat for HCC TreatmentFebruary 12, 2025 | targetedonc.comAmezalpat Receives FDA Fast Track Designation for Hepatocellular CarcinomaFebruary 12, 2025 | oncnursingnews.comTempest Therapeutics granted FTD from FDA for amezalpatFebruary 11, 2025 | markets.businessinsider.comTempest Therapeutics' Amezalpat Receives FDA Fast Track and Orphan Drug Designations for Hepatocellular Carcinoma TreatmentFebruary 10, 2025 | quiverquant.comTempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular CarcinomaFebruary 10, 2025 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comAmezalpat Gains FDA Orphan Drug Status in HCCJanuary 8, 2025 | targetedonc.comTempest Therapeutics Inc (TPST) Stock: More Strategic Than Meets the EyeJanuary 7, 2025 | bovnews.comFDA grants ODD to Tempest’s hepatocellular carcinoma treatmentJanuary 7, 2025 | finance.yahoo.comTempest Therapeutics Receives FDA Orphan Drug Designation for Amezalpat in Hepatocellular Carcinoma TreatmentJanuary 6, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPST Company DescriptionsTempest Therapeutics NASDAQ:TPST$0.77 -0.07 (-8.08%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.78 +0.00 (+0.63%) As of 03/28/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
